Drug class profile · refreshed daily from federal data

Antimetabolite Immunosuppressant

2 molecules in this class, — combined CY2024 Part D spend across — claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Antimetabolite Immunosuppressant class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: —combined across class
Total Rx claims: —— unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Mycophenilic Acid

Brand: Mycophenolic Acid · — Part D claims (CY24) · First FDA approval: 2022-02-21

Brand-only (no generics)

Low NADAC$0.100

→

Avg plan cost$0.161

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Mycophenolic Acid

Brand: Myfortic · — Part D claims (CY24) · First FDA approval: 2004-02-27

Brand-only (no generics) 671 plans require PA

Low NADAC$0.100

→

Avg plan cost$0.898

Part D spend — 9× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.